 |
Celsion Corporation
CLSN
|
15.6 |
- |
-6.63 % |
$ 13.9 M |
USA |
 |
FSD Pharma
HUGE
|
2.94 K |
- |
5743.5 % |
$ 69.7 M |
Canada |
 |
Dynavax Technologies Corporation
DVAX
|
56.5 |
- |
- |
$ 2.02 B |
USA |
 |
I-Mab
IMAB
|
271 |
- |
- |
$ 866 M |
China |
 |
AgeX Therapeutics
AGE
|
186 |
- |
-10.17 % |
$ 12.2 K |
USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 |
- |
- |
$ 40.3 B |
USA |
 |
Qilian International Holding Group Limited
QLI
|
27.9 |
- |
-6.08 % |
$ 184 M |
China |
 |
Happiness Biotech Group Limited
HAPP
|
5.46 |
- |
1.35 % |
$ 17.8 M |
China |
 |
CureVac N.V.
CVAC
|
13.6 |
- |
- |
$ 867 M |
Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K |
- |
-1.52 % |
$ 24.7 M |
USA |
 |
Midatech Pharma plc
MTP
|
204 |
- |
-18.52 % |
$ 27.3 M |
Britain |
 |
Codexis
CDXS
|
30.9 |
$ 1.46 |
2.82 % |
$ 127 M |
USA |
 |
Ardelyx
ARDX
|
58 |
$ 3.78 |
1.89 % |
$ 911 M |
USA |
 |
Affimed N.V.
AFMD
|
31.4 |
- |
-34.95 % |
$ 21.5 M |
Germany |
 |
Arcutis Biotherapeutics
ARQT
|
106 |
$ 23.9 |
1.01 % |
$ 3.04 B |
USA |
 |
Assembly Biosciences
ASMB
|
2.46 |
$ 36.6 |
1.3 % |
$ 410 M |
USA |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
118 |
- |
-1.58 % |
$ 28.1 M |
China |
 |
Celyad Oncology SA
CYAD
|
64.4 |
- |
- |
$ 12.5 M |
Belgium |
 |
Generation Bio Co.
GBIO
|
47.6 |
- |
- |
$ 344 M |
USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
3.66 K |
- |
-4.36 % |
$ 27 M |
USA |
 |
Axsome Therapeutics
AXSM
|
105 |
$ 206.68 |
0.16 % |
$ 10.3 B |
USA |
 |
GlycoMimetics
GLYC
|
303 |
- |
9357.83 % |
$ 1.01 B |
USA |
 |
AnaptysBio
ANAB
|
58 |
$ 56.8 |
0.94 % |
$ 1.63 B |
USA |
 |
Aeterna Zentaris
AEZS
|
146 |
- |
5.93 % |
$ 314 M |
Canada |
 |
BioMarin Pharmaceutical
BMRN
|
88.9 |
$ 66.53 |
0.15 % |
$ 12.8 B |
USA |
 |
BeiGene, Ltd.
BGNE
|
52.6 |
- |
0.49 % |
$ 251 B |
Cayman-islands |
 |
AIkido Pharma
AIKI
|
17.9 |
- |
1.93 % |
$ 17.4 M |
USA |
 |
Aeglea BioTherapeutics
AGLE
|
216 |
- |
- |
$ 1.01 B |
USA |
 |
Bicycle Therapeutics plc
BCYC
|
13.8 |
$ 4.3 |
1.42 % |
$ 298 M |
Britain |
 |
ChromaDex Corporation
CDXC
|
24.7 |
- |
-0.88 % |
$ 598 M |
USA |